Leidos 10-Q Details Q3 Beat, $2.4B Entrust Deal and $100M Divestiture Gain
LDOS sits 42% above its 52-week low of $98.86.
Summary
Leidos' Q3 10-Q backs up the November 2 beat with $4.63 billion of revenue, $1.62 billion of nine-month operating cash flow and $6.0 billion of long-term debt after the $2.4 billion Entrust deal. The SES joint venture closed October 5 with a roughly $100 million Q4 gain expected, while Health segment profit fell 25.9%.
Key Events · Earnings and Guidance · LDOS
-
Q3 Revenue $4.63B, Diluted EPS $3.28
Revenue rose 3.6% to $4,630 million from $4,469 million; net income attributable to Leidos was $410 million and diluted EPS $3.28 versus $2.82 a year earlier.
-
Nine-Month Operating Cash Flow $1.62B
Operating cash flow of $1,617 million versus $1,255 million a year ago funded $2,338 million of Entrust acquisition spending and $766 million of open-market buybacks.
-
Debt Rises to $6.0B After Entrust
Long-term debt, net of current portion, rose to $6,009 million from $4,628 million at January 2, 2026, after issuing $600 million of 4.10% 2029 notes and $800 million of 5.00% 2036 notes; the $1.5 billion revolver is undrawn and covenants were met.
-
SES Joint Venture Closes, ~$100M Q4 Gain
The SES Business was contributed to a joint venture with Altaris on October 5, 2026; Leidos retains 41.5% and expects a non-operating gain of approximately $100 million in Q4 FY26, with Homeland revenue lower as a result.
Analysis · LDOS · Technology
The headline numbers were already out on November 2, but the 10-Q is where the balance sheet and cash flow land: nine-month operating cash flow of $1,617 million funded $2,338 million of Entrust acquisition spending and $766 million of buybacks, while long-term debt climbed to $6,009 million from $4,628 million. The SES joint venture closed October 5 and Leidos expects roughly a $100 million non-operating gain in Q4, which will flatter reported earnings even as Homeland revenue steps down. The soft spot is Health, where revenue fell 11.7% and operating income 25.9% on lower managed health services volumes and incentive fees — the one segment trend that could pressure the raised guidance.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LDOS was trading at $140.01 on NYSE in the Technology sector, with a market capitalization of approximately $17.6B. The 52-week trading range was $98.86 to $205.77. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.